LOS ANGELES--(BUSINESS WIRE)--Mar 20, 2010 - Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the common stock of Cell Therapeutics, Inc. (“Cell Therapeutics” or the “Company”) (NASDAQ:CTIC) between May 5, 2009 and February 8, 2010, inclusive (the “Class Period”).
MELVILLE, N.Y.--(BUSINESS WIRE)--Mar 19, 2010 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease following four cycles of standard platinum-based first-line chemotherapy. A final decision is expected from the European Commission within 45 days.
NEW YORK--(BUSINESS WIRE)--Mar 19, 2010 - Synergy Pharmaceuticals, Inc. (OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC).
ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 19, 2010 - Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Barclays Capital 2010 Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com
DEERFIELD, Ill.--(BUSINESS WIRE)--Mar 19, 2010 - Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its first quarter 2010 financial results on Thursday, April 22, 2010, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar 19, 2010 - A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV).
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Astellas' proposed acquisition of OSI Pharmaceuticals Inc. (NASDAQ:OSIP) has expired.
Mechelen, Belgium; 19 March 2010 - Galapagos NV (Euronext: GLPG) announced the decision to pursue cystic fibrosis (CF) in its strategy to deliver breakthrough medicines to patients with orphan diseases. Details of Galapagos' CF program and its pipeline of 4 clinical and over 50 pre-clinical and discovery programs will be discussed during the R&D Update presentation webcast later today.
BOSTON, March 19 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (NASDAQ:PRXL) announced today it will be presenting at the Barclays Capital Global Healthcare Conference in Miami, Florida. Josef von Rickenbach, Chairman & Chief Executive Officer will be making a formal presentation on PAREXEL at 1:30 p.m. ET on Tuesday, March 23, 2010.
PRINCETON, N.J., March 19 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (NASDAQ:DSCI) , a specialty medical device/pharmaceutical company focused on advanced wound care, will present at the RedChip New York Equities Growth Conference on March 23, 2010 at 2:30 pm EDT. The event will be held at the NASDAQ Market Site in New York City's Times Square. Edward J. Quilty, CEO of Derma Sciences will provide attendees with an overview of the company's business operations and investment highlights.
Pennington, NJ, March 20, 2010 —Creative MediaWorks is pleased to announce that their Graphics Division has added Stephanie Rutkowsky to their team. Prior to joining CMW, Stephanie worked at the Lenox Corporation as a Graphic Merchandising Specialist.
PASADENA, Calif.--(BUSINESS WIRE)--Mar 19, 2010 - GenMark Diagnostics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. GenMark is a Delaware corporation and, in connection with the offering, will become the parent holding company of Osmetech, plc.
ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a binding agreement to acquire a private branded generics and over the counter (OTC) company located in Brazil for approximately US$28 million.
BERKELEY, Calif., March 19 /PRNewswire/ -- NeuroFocus, the world's leading neuromarketing company, announced today that Nobel Prize laureate Eric R. Kandel, M.D., has joined its Advisory Board. Dr. Kandel is a winner of the Nobel Prize for Medicine or Physiology for his seminal contributions to the field of neuroscience. Specifically, he was recognized with this top honor for his research on the physiological basis of memory storage in neurons.
COSTA MESA, Calif.--(BUSINESS WIRE)--Mar 19, 2010 - SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that Reese Pharmaceutical Company has selected SYSPRO ERP (Enterprise Resource Planning) software to run its private labeling and distribution operations.
EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (NASDAQ:VPHM) today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions.
FLORENCE, Italy and EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (NASDAQ:VPHM) today announced the presentation of two abstracts relating to Cinryze (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.
MOUNTAIN VIEW, Calif., March 19 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Barclays Capital 2010 Global Healthcare Conference.
CAMBRIDGE, England, March 19, 2010/PRNewswire/ -- Mundipharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member States of the EU: Austria, Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the United Kingdom (UK) for the use of bendamustine in the treatment of patients with indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM).
BRISTOL, TN--(Marketwire - March 19, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) today announced plans to provide a presentation on Wednesday, March 24, 2010, at 2:30 p.m. ET, at the Barclays Capital 2010 Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida. The presentation may include a discussion of the Company's marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business
|
